ArticleJournal of neuroendocrinology2026
Relative and normalized iodine concentrations derived from photon counting computed tomography and their correlation with tumor grade and Ki67 in pancreatic neuroendocrine neoplasia: A pilot study.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms are a rare and complex tumor entity, among which pancreatic neuroendocrine neoplasms generally display a more aggressive behavior. Despite a notable stage migration towards lower stages at initial diagnosis, the incidence of pancreatic neuroendocrine neoplasms is rising. In recent publications, iodine concentration derived from dual energy computed tomography was explored as a potential biomarker for pancreatic neuroendocrine neoplasia tumor grade and Ki67. However, methodologies exhibited significant variability, and reported outcomes were ambiguous, ranging from weak correlations to strong predictive performance in complex multivariate analyses. With the advent of photon counting computed tomography and improved technical capabilities, this study revisits the topic and aims to provide evidence for tumor characterization using photon counting computed tomography-derived iodine concentration in pancreatic neuroendocrine neoplasms. Iodine concentration in neuroendocrine pancreatic primaries was analyzed in the portal venous phase regarding correlation with histopathological tumor grade and Ki67. Iodine concentration was normalized to aortic iodine concentration (normalized iodine concentration), as well as calculated relative to unaffected pancreatic tissue (relative iodine concentration). Correlations were analyzed using Spearman's rank correlation, and mean concentrations were analyzed using Mann-Whitney U test. Eighteen cases with pancreatic neuroendocrine neoplasms were included. Relative Iodine concentration exhibited a strong and statistically significant correlation with tumor grade (ρ = 0.54, p = 0.02) and Ki67 (ρ = 0.53, p = 0.02). Mean relative iodine concentration was higher in high-grade tumors (p = 0.02). Normalized iodine concentration showed weak, non-significant correlations with tumor grade (ρ = 0.33, p = 0.18) and Ki67 (ρ = 0.30, p = 0.22). Mean normalized iodine concentration did not differ significantly between low-grade and high-grade pancreatic NEN. Our preliminary results show that photon counting computed tomography derived iodine concentration and especially relative iodine concentration is a potential biomarker for tumor grade and Ki67 prediction with strong, statistically significant correlations in untreated pancreatic neuroendocrine neoplasms. The method is non-invasive, requires little to no additional resources and may support early, evidence-based therapeutic decisions even before primary tumor biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.